Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES

NCT05203172 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05203172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENCORAFENIB/BINIMETINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIES
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Recruiting
Start date
July 5, 2022
Completion date
June 30, 2032
Enrollment
210 (estimated)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors